Search

Your search keyword '"Cécile Brunet-Cartier"' showing total 6 results
Start Over Author "Cécile Brunet-Cartier"
6 results on '"Cécile Brunet-Cartier"'

1. Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination

Author

Maeva, Lefebvre, Solène, Secher, Sabelline, Bouchez, Yves-Marie, Vandamme, Pascale, Fialaire, Sophie, Leautez, Sophie, Blanchi, Christophe, Michau, Marianne, Coste-Burel, Cécile, Brunet-Cartier, Véronique, Reliquet, Antoine, Gregoire, François, Raffi, and Clotilde, Allavena

Subjects
Adult, Cross-Sectional Studies, Seroepidemiologic Studies, Measles Vaccine, Vaccination, HIV, Humans, Female, HIV Infections, Antibodies, Viral, Measles
Abstract

Widespread use of the measles vaccine should lead to the elimination of this disease. Here, we study the seroprevalence of measles in a cohort of adults living with HIV born after the introduction of measles vaccine in France and attempt to identify risk factors for the absence of serum measles antibody.In this multi-centre cross-sectional study, adult outpatients born after 1980 were screened for the presence of measles IgG antibody. Demographic and clinical data were obtained from the standardized electronic medical record system. Univariate and multivariate logistic regressions were performed to identify factors associated with the absence of measles antibodies.Between April 2019 and April 2020, 648 participants were enrolled. The median age was 33 years, 53.6% were born outside of France, and 74% were considered as socially deprived. Plasma HIV RNA was undetectable in 86% of patients. Among 603 evaluable patients, measles serology was positive in 87.2%. Only 81.8% of the patients with documented vaccination tested positive for measles IgG. Younger age was significantly associated with the absence of measles serum antibodies ( P = 0.004 for each 10-year lower), as was birth in France ( P 0.001) and absence of social vulnerability ( P = 0.04).The current study revealed a low seroprevalence of measles compared with that previously reported in France 6 years earlier and to the expected rate to achieve herd immunity. Checking vaccination record should be systematically carried out in patients living with HIV to fill the immunity gaps.

Published
2022

2. Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

Author

Jérôme Le Chenadec, Anrs Epf Co, Pierre Frange, Ana Canestri, Roland Tubiana, Laurent Mandelbrot, Josiane Warszawski, Cécile Brunet-Cartier, Laurent Cotte, Jeanne Sibiude, Jacques Reynes, Cédric Arvieux, and Centre for Reproductive Medicine - Gynaecology

Subjects
0301 basic medicine, Microbiology (medical), safety, medicine.medical_specialty, RFC, Anti-HIV Agents, HIV Infections, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Obstetrics and Gynaecology, medicine, Emtricitabine, Humans, Pharmacology (medical), 030212 general & internal medicine, Pharmacology, business.industry, Obstetrics, Rilpivirine, Infant, Newborn, Gestational age, Viral Load, medicine.disease, 030112 virology, 3. Good health, HIV-1-positive, Regimen, Infectious Diseases, chemistry, Cohort, HIV-1, Gestation, Ritonavir, Female, women, business, Viral load, medicine.drug
Abstract

BackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (ResultsAmong 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was ConclusionsIn virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes.

Published
2019

3. Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants

Author

François Raffi, Véronique Reliquet, Cécile Brunet-Cartier, and Elise Launay

Subjects
0301 basic medicine, Response rate (survey), Pediatrics, medicine.medical_specialty, Transmission (medicine), business.industry, 030106 microbiology, Human immunodeficiency virus (HIV), Cancer, Cognition, medicine.disease, medicine.disease_cause, Antiretroviral therapy, 03 medical and health sciences, 0302 clinical medicine, In utero, Pediatrics, Perinatology and Child Health, medicine, Original Article, 030212 general & internal medicine, business, Adverse effect
Abstract

Background: Antiretroviral therapy (ART) in HIV pregnant women has led to a dramatic decrease in the rate of HIV mother-to-child transmission but this benefit is counterbalanced with adverse effects related to in utero and neonatal exposure to ART. In 2013, some parents described neurodevelopmental disorders in their children. Methods: A standardized letter was sent to the 133 women who delivered in Nantes hospital from 01/01/2003 to 31/12/2012 (167 births). Results: Response rate was 33%. Over a 10-year period, 7 children had behavioral disorders and/or cognitive/developmental delay, 1 child had developmental delay + growth retardation and 2 experienced cancer. Conclusions: We found a significant association between neurodevelopmental disorders, preterm birth and exposure to 3 nucleoside reverse transcriptase inhibitors (NRTIs). Further studies are needed and long-term follow-up into adulthood should continue.

Published
2017
Full Text
View/download PDF

4. Does changing antiretroviral therapy in the first trimester for pregnancy-related concerns have an impact on viral suppression ?: Changing ART in pregnancy and viral suppression ?

Author

Josiane Warszawski, Agnès Bourgeois-Moine, Caroline Simon Toulza, Albert Faye, Violaine Peyronnet, Laurent Mandelbrot, Eida Bui, Jérôme Le Chenadec, Jeanne Sibiude, Cécile Brunet-Cartier, Olivia Dialla, Véronique Avettand-Fenoel, Roland Tubiana, Delphine Peretti, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Département d'obstétrique et de gynécologie [AP-HP Hôpital Louis-Mourier] (DHU Risks in Pregnancy), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris-Sud [Le Kremlin-Bicêtre] (Faculté de Médecine), Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre hospitalier universitaire de Nantes (CHU Nantes), Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Université Paris Descartes - Paris 5 (UPD5), CHU Necker - Enfants Malades [AP-HP], AP-HP Hôpital universitaire Robert-Debré [Paris], Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), This work was supported by the French Agence Nationale de Recherche sur le SIDA (ANRS)., and ANRS EPF-French Perinatal Cohort Study

Subjects
Adult, viral suppression, medicine.medical_specialty, Anti-HIV Agents, antiretroviral therapy, HIV Infections, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pregnancy, Medicine, Humans, Pharmacology (medical), guidelines, 030212 general & internal medicine, Prospective Studies, Young adult, Pregnancy Complications, Infectious, Prospective cohort study, Propensity Score, Survival analysis, preconception care, 0303 health sciences, 030306 microbiology, business.industry, Obstetrics, Drug Substitution, Pregnancy Outcome, HIV, Viral Load, medicine.disease, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], Survival Analysis, Infectious Disease Transmission, Vertical, 3. Good health, treatment switch, Pregnancy Trimester, First, Infectious Diseases, Logistic Models, Cohort, Propensity score matching, HIV-1, Gestation, Female, business, Viral load
Abstract

International audience; OBJECTIVE:To determine whether changing antiretroviral therapy (ART) during pregnancy because of concern about fetal risks led to poorer virological outcomes.METHODS:All pregnancies in women with HIV-1 infection enrolled in the national multicenter prospective French Perinatal cohort at 14 week gestation or more were included between January 2005 and December 2015, if the mother was on ART at conception with a plasma viral load

Published
2019
Full Text
View/download PDF

5. Does Changing Antiretroviral Therapy in the First Trimester for Pregnancy-Related Concerns Have an Impact on Viral Suppression?

Author

Olivia Dialla, Violaine Peyronnet, Josiane Warszawski, Laurent Mandelbrot, Delphine Peretti, Jérôme Le Chenadec, Caroline Simon Toulza, Eida Bui, Cécile Brunet-Cartier, Roland Tubiana, Véronique Avettand-Fenoel, Albert Faye, Jeanne Sibiude, and Agnès Bourgeois Moine

Subjects
Pregnancy, medicine.medical_specialty, biology, Obstetrics, business.industry, medicine.disease, biology.organism_classification, Informed consent, Propensity score matching, Cohort, medicine, Gestation, Sida, business, Viral load, Survival analysis
Abstract

Objective: To determine whether changing antiretroviral therapy (ART) during pregnancy in order to follow guidelines because of concern about fetal risks led to poorer virological outcomes. Methods: All pregnancies in women with HIV1 infection enrolled in the national multicenter prospective French Perinatal cohort were included between 01/2005 and 12/2015, at 14 gestational weeks or more and if the mother was on ART at conception with a plasma viral load < 50 copies/ml. The reasons for a change in the ART were analyzed according to treatment guidelines at the time of the pregnancy, and defined as for pregnancy-related concerns in the absence of reported maternal intolerance. Virological and pregnancy outcomes were studied by survival analysis and logistic regression adjusted for a propensity score established for each patient according to baseline characteristics. Results: Of 10553 pregnancies in the cohort, 1797 were taking ART at conception and had a viral load

Published
2018
Full Text
View/download PDF

6. Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a European country

Author

Marie Medus, Vincent Gajdos, Laure Clech, Céline Goissen, Arnaud Chalvon Demersay, Virginie Zarouk, Louis Bernard, Pierre-François Ceccaldi, René-Charles Rudigoz, Patricia Murger, Philippe Le Moine, Catherine Chirouze, Mandovi Rajguru, Ludovic Cravello, Véronique Lefevre Elbert, Luminata Shneider, Guy Leverger, Tessa Goetghebuer, Kamila Kebaili, Eliane Galiba, Claudine Touboul, Françoise Meier, Didier Tardif, Dieudoné Ekoukou, Michèle Granier, Ahmed Zakaria, Corinne Cudeville, Laurence Benoist, Emilie Piet, Emmanuelle Vintejoux, Yves Hatchuel, Christophe Michau, Jean-Luc Schmidt, Michel Françoise, Claire Briandet, Stéphane Blanche, Philippe Bailly-Salin, Anne Vanderbergh, Jeanne Sibiude, Christiane Kommé, Benoît Martha, Camille Runel-Belliard, Claire Pluchart, Imad Nahri, Vincent Jeantils, François Hervé, Isabelle Hau, Agnès Lefort, Dominique Ayral, Delphine Peretti, Stéphanie Proust, Marie Belloy, Christine Rouzioux, Arnaud Boutet, Philippe Van de Perre, Elisabeth Broustal, Cécile Hafner Mauvais, Thierry Pistone, Marie-Dominique Tabone, Hélène Dauphin, Laurent Cotte, Clement Taron-Brocard, Jean-Marie Lang, Christine Boissinot, Antoine Doumet, André Bongain, Narcisse Elenga, Geneviève Mouchnino, Anne Boutemy, Christine Cheneau, Pascale Perfezou, Pierre Frange, Mathilde Niault, Christelle Dupre, Anne Chacé, Jean-Paul Teglas, Corinne Daniel, Sophie Matheron, Severine Ansart, Martine Levine, Fabienne Caby, Marc Duval-Arnould, Isabelle Metheron, Kareen Billiemaz, Albert Faye, Didier Armangaud, Yamina Hammou, Neila Elaoun, Anne Deville, Philippe Arsac, Lydie Sanchez, Odile Luycx Vaillant, Philippe Lumbroso, Marie-Gisèle Lebrette, Norbert Winer, Elise Maurel, Ramona Abrudan, Luc De Saint Martin, Françoise Jacquier, Christian Calvez, Fabrice Monpoux, Louis Mesnard, Marie-Aude Khuong-Josses, David Rey, Isabelle Belzic, Christine Allisy, Claire Genet, Hervé Seaume, Roland Tubiana, Jacques Reynes, Pascale Nau, Gilles Blondin, Eric Lachassine, Yves Poinsignon, Cédric Arvieux, Leila Karaoui, Anaïs Perilhou, Amélie Benbara, Marine Joras, Sophie Leautez-Nainville, Sophie Ducroix-Roubert, Raghad Moalim, Pascal Bolot, Jacques Gaillat, Olivier Bollengier Stragier, Alain Devidas, Muriel Lalande, Delphine Lemercier, Jean-Pierre Brossier, Emmanuelle Boutard, Isolde Pauly-Ravelly, Marie-Françoise Le Coz, Anne Grelier, Alain Alissa, Christiane De Gennes, Jean-Luc Delassus, Emmanuel Mortier, Faiza Ajana, Ghislaine Firtion, Alain Berrebi, Rose Nguyen, Sarah Ducrocq, Jean-Marc Chamouilli, Fabienne Mazy, Maïa Banigé, Khaled Mohamed, Natacha Entz-Werle, Jacques Brouard, Germaine Bachelard, Sandrine Delmas, Anne Constanty, Véronique Reliquet, Sophie Couderc, Florence Veber, Lahcene Allal, Catherine Crenn-Hebert, Blandine Muanza, Gaelle Pinto-Cardoso, Laurent Mandelbrot, Ama Johnson, Fabienne Messaoudi, Christian Burle, Josiane Warszawski, Bénédicte Carpentier, Dominique Brault, Suzanne Braig, Pascale Fialaire, Corinne Fourcade, Elisabeth Questiaux, Véronique Chambrin, Alain Lafeuillade, Véronique Hentgen, Yves Aubrard, Anne Borgne, Sandrine-Anne Martha, Evelyne Werner, Corinne Floch-Tudal, Agnès Bourgeois Moine, Corinne Routier, Jérôme Le Chenadec, Anne Coursol, Alain Fisher, Amélie Chabrol, Cécile Winter, Cécile Brunet-Cartier, Philippe Labrune, Claudine Cayla, Françoise Mazingue, Virginie Vitrat, Cyril Clavel, Michel Segondy, Ruxandra-Oana Calin, Lise Selleret, Pierre Weinbreck, Zaitoun Abdallah Moussa, Joël Gaudelus, Gaetane Mousset, Thomas Guimard, Agnès Villemant Uludag, Emmanuelle Pannier, Brigitte Clavier, Nicole Ciraru-Vigneron, Alain Checoury, Christophe Elleau, Manuela Bonmarchand, Catherine Dollfus, Joëlle Dendale-Nguyen, Adrien May, Pierre Chevojon, Claire Hubert, Constance Borie, Marialuisa Partisani, Elie Azria, Edouard Vaucel, Erianna Bellaton Marouts, Philippe Moreau, Jean-Luc Esnault, Mahfoud Rouha, Mary-France Courcoux, Brigitte Heller-Roussin, Gilles Hittinger, Christine Rouger, Lanto Ratsimbazafy, Jean-Marc Labaune, Mohamed Abdelhadi, Brigitte Elharrar, Joëlle Tricoire, Eric David, Hassan Safwan, Karine Guimard, Bruno Carbonne, Muriel Barat, Marion Dehlinger-Paul, Stéphane Bounan, Myriam Costa, Estelle Bauville, Didier Pinquier, Valérie Garrait, Etienne Dienga, Odile Launay, Zoha Maakroun, and Dominique Salmon Ceron

Subjects
Microbiology (medical), Pediatrics, medicine.medical_specialty, medicine.medical_treatment, Human immunodeficiency virus (HIV), HIV Infections, Kaplan-Meier Estimate, medicine.disease_cause, Infant, Newborn, Diseases, Pregnancy, medicine, Humans, Pregnancy Complications, Infectious, Retrospective Studies, business.industry, Proportional hazards model, Risk of infection, Hazard ratio, Infant, Newborn, Infant, Immunosuppression, Bacterial Infections, medicine.disease, Confidence interval, Infectious Disease Transmission, Vertical, CD4 Lymphocyte Count, Infectious Diseases, Immunology, Cohort, Female, France, business, Immunosuppressive Agents
Abstract

BACKGROUND Morbidity and mortality are higher among human immunodeficiency virus (HIV) exposed but uninfected (HEU) infants than unexposed infants, particularly if the mother had a low CD4 count. We investigated the possible association between maternal immune depression during pregnancy and the risk of infection in HEU infants in the national French Perinatal Cohort (EPF). METHODS All neonates, born alive, to HIV-1-infected women enrolled in the EPF between 2002 and 2010 were included. The primary outcome was the first serious (hospitalization or death) infection during the first year of life. The main exposure variable was maternal CD4 cell count near delivery. The Kaplan-Meier method and multivariate Cox models were applied, with the different types of infections managed as competing events. RESULTS Among 7638 HEU neonates, 699 had at least 1 serious infection (of which 159 were bacterial) with a Kaplan-Meier probability of 9.3% (95% confidence interval, 8.7-10.0) at 1 year. The risk of serious bacterial infection during the first year of life significantly increased with lower maternal CD4 cell count, before and after adjustment for maternal CD4 cell count

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results